工程化补体因子H构建体用于治疗C3肾小球病
C3肾小球病(C3G)与补体替代途径失调相关且治疗有限。研究者在迷你FH(FH1-5^18-20)上引入FHR1的寡聚化结构域,构建两种同源二聚体迷你FH,体外显示强结合与抑制补体活性,在FH缺陷小鼠中限制C3沉积并延长血清半衰期,提示FH1-5^18-20^R1-2可能成为C3G治疗选择。
要点
- 两种同源二聚体迷你FH在体外抑制细胞表面补体活性均>10倍于FH。
- FH1-5^18-20^R1-2血清t1/2较FH1-5^18-20提高>5倍且在肾脏保留更佳。
- 两种构建体在体内限制肾小球基底膜C3沉积显著优于FH或FH1-5^18-20。
核心结论
- FH1-5^18-20^R1-2可能作为C3G或其他补体介导疾病的治疗选择。
研究设计与样本
- 在CHO细胞中构建两种人FH1-5^18-20与FHR1寡聚化域(R1-2)融合的同源二聚体迷你FH(FHR1-2^1-5^18-20和FH1-5^18-20^R1-2),行结合、液相和红细胞裂解试验,并在FH缺陷Cfh-/-小鼠中验证。
主要发现
- 两种构建体在溶液中同源二聚化,在聚集C3b表面显示强结合,尤其FHR1-2^1-5^18-20。
- 每种构建体在体外抑制细胞表面补体活性均>10倍于FH。
- 两种构建体在体内限制肾小球基底膜C3沉积显著优于FH或FH1-5^18-20。
- FH1-5^18-20^R1-2的C3裂解片段结合谱与FH相似。
- FH1-5^18-20^R1-2的血清t1/2较FH1-5^18-20提高>5倍,且肾脏保留显著优于FH或FH1-5^18-20。
临床怎么用
- FH1-5^18-20^R1-2可能为C3G或其他补体介导疾病提供候选治疗,尚需进一步临床研究验证。
局限性
- 研究仅在体外及FH缺陷小鼠中进行,尚未在人体或C3G患者中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background C3 glomerulopathy (C3G) is associated with dysregulation of the alternative pathway of complement activation, and treatment options for C3G remain limited. Complement factor H (FH) is a potent regulator of the alternative pathway and might offer a solution, but the mass and complexity of FH makes generation of full-length FH far from trivial. We previously generated a mini-FH construct, with FH short consensus repeats 1-5 linked to repeats 18-20 (FH1-5^18-20), that was effective in experimental C3G. However, the serum t1/2 of FH1-5^18-20 was significantly shorter than that of serum-purified FH.Methods We introduced the oligomerization domain of human FH-related protein 1 (denoted by R1-2) at the carboxy or amino terminus of human FH1-5^18-20 to generate two homodimeric mini-FH constructs (FHR1-2^1-5^18-20 and FH1-5^18-20^R1-2, respectively) in Chinese hamster ovary cells and tested these constructs using binding, fluid-phase, and erythrocyte lysis assays, followed by experiments in FH-deficient Cfh-/- mice.Results FHR1-2^1-5^18-20 and FH1-5^18-20^R1-2 homodimerized in solution and displayed avid binding profiles on clustered C3b surfaces, particularly FHR1-2^1-5^18-20 Each construct was >10-fold more effective than FH at inhibiting cell surface complement activity in vitro and restricted glomerular basement membrane C3 deposition in vivo significantly better than FH or FH1-5^18-20 FH1-5^18-20^R1-2 had a C3 breakdown fragment binding profile similar to that of FH, a >5-fold increase in serum t1/2 compared with that of FH1-5^18-20, and significantly better retention in the kidney than FH or FH1-5^18-20Conclusions FH1-5^18-20^R1-2 may have utility as a treatment option for C3G or other complement-mediated diseases.
引用
- Yang Y, Denton H, Davies OR, et al. An Engineered Complement Factor H Construct for Treatment of C3 Glomerulopathy. J Am Soc Nephrol. 2018. PMID: 29588430. doi:10.1681/ASN.2017091006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。